In conjunction with the launch, we've been pleased with our improved access to neurology movement disorder practices. We're seeing that the launch of ONGENTYS has helped drive higher neurology call volume for INGREZZA, which we expect to benefit our efforts in TD. So heading into year-end, we will continue to introduce ONGENTYS to the Parkinson's community and execute against our launch plan. Our aspiration is not only to displace current COMT inhibitors, but also to be prescribed earlier and earlier in the treatment paradigm ahead of alternative adjunctive treatments from other drug classes.